Reltecimod-AB-103-DataSheet-生命科学试剂-MedChemExpress

Hotline:400-820-3792Inhibitors•ScreeningLibraries•Proteinswww.MedChemEReltecimodCat.No.:HY-P1698CASNo.:1447799-33-8Synonyms:AB-103分⼦式:C₄₆H₇₂N₁₀O₁₅S分⼦量:1037.19SequenceShortening:ASPMLVAYDA作⽤靶点:Bacterial;CD28作⽤通路:Anti-infection;Immunology/Inflammation储存⽅式:PleasestoretheproductundertherecommendedconditionsintheCertificateofAnalysis.BIOLOGICALACTIVITY⽣物活性Reltecimod(AB-103)⼀种T细胞特异性表糖蛋⽩CD28(TP44)拮抗剂。Reltecimod对不同的细感染、细外毒素和内毒素以及电离辐射都有良好的抗性作⽤。Reltecimod通过靶向和减弱关键的CD28/B7-2共刺激通路来调节炎症反应，⽽不抑制它。Reltecimod可⽤于研究坏死性软组织感染(NSTIs)。IC50&TargetTP44,Bacteria[1][2]体内研究Reltecimod(1.25-5mg/kg;i.v.)increasesthesurvivalrateofmiceinfectedwithdifferentbacteria[2].AnimalModel:Pathogen-free,femaleBALB/cmice(Acutebacterialperitonitiswasinducedbyi.p.administrationwithE.coli018:K1)[2]Dosage:1.25or5mg/kgAdministration:i.v.;singledosage;at4hpostinfectionResult:Resultedin100%survivalatsingledosageof5mg/kg,atday6.Resultedin70%survivalat4dosage(at1,12,24and36hpostinfection)of1.25mg/kg,atday6.AnimalModel:Pathogen-free,femaleBALB/cmice(NSTIinducedbythighi.m.administrationwith1/2MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemEStreptococcuspyogenes)[2]Dosage:2.5or5mg/kgAdministration:i.v.;singledosage;at1h,orat1hand12or72hpostinfectionResult:Resultedin65%survivalatsingledosageof2.5mg/kg,atday8.Resultedin30%survivalattwodosage(1and12hpostinfection)of2.5mg/kg,atday8.Resultedin90%survivalatsingledosage(1hpostinfection)of5mg/kg,atday6.AnimalModel:Pathogen-free,femaleBALB/cmice[Cecalligationandpuncture(CLP)model][2]Dosage:1.25,2.5,or5mg/kgAdministration:i.v.;singledosageResult:Increasedday7survivalbyupto100%.REFERENCES[1].Shirvan,A.,etal.Reltecimod.T-cell-specificsurfaceglycoproteinCD28(TP44)antagonist,CD28homodimerinterfacemimeticpeptide,Treatmentofnecrotizingsoft-tissueinfection.DrugsFut2018,43(4):243[2].Edgar,R.,Tarrio,M.L.,Maislin,G.etal.TreatmentwithOneDoseofReltecimodisSuperiortoTwoDosesinMouseModelsofLethalInfection.IntJPeptResTher26,1669–1683(2020).McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchus